Does your family have a mutation on one of three known genes that causes Alzheimer’s disease? OR Does your family have 3 generations of Alzheimer's disease that starts younger than age 60?
The DIAN Expanded Registry is registering this specific group of people for drug trials. If you answered Yes to either question above, you may qualify to enroll if:
1. You are over 18 years old AND have a parent or sibling that has/had dominantly inherited Alzheimer’s disease.
2. You would be willing to be part of a drug study to test a drug that may slow down or prevent memory loss.
About the Study:
The DIAN Expanded Registry is an international registry for Autosomal Dominant Alzheimer's disease (ADAD) drug trials. The purpose of the DIAN Expanded Registry is to provide participants with current and future research opportunities focused on autosomal dominant Alzheimer’s disease. The two studies which are currently recruiting are the DIAN Observational study and the DIAN-TU therapeutic trial.
Autosomal dominant Alzheimer’s disease (ADAD) is a rare form of Alzheimer’s disease caused by mutations in one of three genes (PS1, PS2, APP). ADAD affects families across multiple generations, and symptoms appear at a young age, typically when a person is in their 30s to 50s. ADAD is very rare, as it makes up only around 1% of the total cases of Alzheimer’s disease.
The DIAN Expanded Registry allows those who sign up to receive information about current and future research opportunities for individuals and families who have ADAD mutations. In addition, registrants receive periodic updates about advances in ADAD research.
What is Involved:
You can register by visiting the DIAN Expanded Registry website at www.dianexr.org. You will be asked to read and agree to a document which asks permission to store your contact information and other information you provide to the registry to establish your eligibility, on a secured research server. We will contact you about present and future research opportunities.